K. Mitsuyama et al., SOLUBLE INTERLEUKIN-6 RECEPTORS IN INFLAMMATORY BOWEL-DISEASE - RELATION TO CIRCULATING INTERLEUKIN-6, Gut, 36(1), 1995, pp. 45-49
The in vivo appearance of soluble interleukin (IL)-6 receptor (sIL-6R)
in serum from patients with inflammatory bowel disease was examined u
sing an enzyme Linked immunosorbent assay (ELISA). The serum sIL-GR co
ncentrations in patients with active disease (ulcerative colitis, 148.
4 (5.1); Crohn's disease, 142.3 (9.3) ng/ml; mean (SEM)) were signific
antly raised compared with those in patients with inactive disease (ul
cerative colitis, 116.2 (7.2); Crohn's disease, 114.3 (7.1) ng/ml), so
me other type of colitis (104.8 (11.6) ng/ml), or in normal subjects (
107.3 (2.4) ng/ml). These differences were also seen in paired samples
examined during both active and inactive phases. Additionally, serum
sIL-GR and IL-6 concentrations correlated significantly with C-reactiv
e protein levels in both ulcerative colitis and Crohn's disease patien
ts (r=0.23 and 0.56, respectively; p<0.05 for both). Furthermore, gel
filtration analysis of serum from these patients showed two major peak
s of immunoreactive IL-6 - one peak corresponding to free IL-6 and ano
ther peak to sIL-6R-bound IL-6 - this was further confirmed by a lumin
escence sandwich ELISA. These results, together with its in vitro effe
cts, indicate that natural sIL-6R may function as a powerful enhancer
of the IL-6-dependent immune processes observed in inflammatory bowel
disease.